Stimulation of insulin-like growth factor binding protein-1 synthesis by interleukin-1β: Requirement of the mitogen-activated protein kinase pathway

Robert A. Frost, Gerald J. Nystrom, Charles H. Lang

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Insulin-like growth factor (IGF) binding protein-1 (IGFBP-1) is a 28-kDa plasma protein that binds to IGF-I and IGF-II with high affinity. IGFBP-1 is elevated in the blood as a result of sepsis, AIDS, excessive alcohol consumption, and diabetes and may, in part, be responsible for the wasting observed during these pathophysiological conditions. The liver is the principal site of IGFBP-1 synthesis, and we have previously shown that proinflammatory cytokines can directly stimulate IGFBP-1 secretion in a human hepatoma cell line (HepG2). The purpose of the present study was to investigate the role of the MAP kinase pathway in regulating IGFBP-1 synthesis by IL-1β. We show that IL-1β stimulates the phosphorylation of ERK-1 and -2 in a time- and dose-dependent manner. In addition, the MAP kinase-kinase MEK-1 and the ribosomal S6-kinase RSK-1 are also phosphorylated in response to IL-1β. The transcription factor CREB, a potential substrate of both protein kinase A (PKA) and RSK-1, is phosphorylated in response to IL-1β and cAMP in HepG2 cells. The ability of IL-1β to stimulate the expression of IGFBP-1 and the phosphorylation of the above kinases was specifically inhibited by PD98059, a MEK-1 inhibitor, cAMP also stimulated IGFBP-1 synthesis, but PD98059 failed to block the cAMP effect. Conversely, a PKA inhibitor (H-89) inhibited the ability of cAMP, but not IL-1β to stimulate IGFBP-1 synthesis. The effect of IL-1β and cAMP on IGFBP-1 messenger RNA (mRNA) accumulation was additive. IL-1β, cAMP, PD98059, and H-89 had similar effects on the accumulation of IGFBP-1 protein and mRNA. IL-1β and cAMP did not change the half-life of IGFBP-1 mRNA, but PD98059 and SB202190, a p38 MAP kinase inhibitor, destabilized IGFBP-1 mRNA and blocked the phosphorylation of RSK-1 in response to IL-1β. Our data demonstrate that the MAP kinase signal transduction pathway plays an important role in the regulation of IGFBP-1 synthesis by IL-1β.

Original languageEnglish (US)
Pages (from-to)3156-3164
Number of pages9
JournalEndocrinology
Volume141
Issue number9
DOIs
StatePublished - Jan 1 2000

Fingerprint

Insulin-Like Growth Factor Binding Protein 1
Mitogen-Activated Protein Kinases
Interleukin-1
Messenger RNA
Aptitude
Phosphotransferases
Mitogen-Activated Protein Kinase Kinases
Phosphorylation
Cyclic AMP-Dependent Protein Kinases
MAP Kinase Kinase 1
Ribosomal Protein S6 Kinases
Insulin-Like Growth Factor II
Hep G2 Cells
p38 Mitogen-Activated Protein Kinases
Protein Kinase Inhibitors
Insulin-Like Growth Factor I
Alcohol Drinking
Half-Life
Blood Proteins

All Science Journal Classification (ASJC) codes

  • Endocrinology

Cite this

@article{e3bb1469da4142a1a10ea3b0c81f183f,
title = "Stimulation of insulin-like growth factor binding protein-1 synthesis by interleukin-1β: Requirement of the mitogen-activated protein kinase pathway",
abstract = "Insulin-like growth factor (IGF) binding protein-1 (IGFBP-1) is a 28-kDa plasma protein that binds to IGF-I and IGF-II with high affinity. IGFBP-1 is elevated in the blood as a result of sepsis, AIDS, excessive alcohol consumption, and diabetes and may, in part, be responsible for the wasting observed during these pathophysiological conditions. The liver is the principal site of IGFBP-1 synthesis, and we have previously shown that proinflammatory cytokines can directly stimulate IGFBP-1 secretion in a human hepatoma cell line (HepG2). The purpose of the present study was to investigate the role of the MAP kinase pathway in regulating IGFBP-1 synthesis by IL-1β. We show that IL-1β stimulates the phosphorylation of ERK-1 and -2 in a time- and dose-dependent manner. In addition, the MAP kinase-kinase MEK-1 and the ribosomal S6-kinase RSK-1 are also phosphorylated in response to IL-1β. The transcription factor CREB, a potential substrate of both protein kinase A (PKA) and RSK-1, is phosphorylated in response to IL-1β and cAMP in HepG2 cells. The ability of IL-1β to stimulate the expression of IGFBP-1 and the phosphorylation of the above kinases was specifically inhibited by PD98059, a MEK-1 inhibitor, cAMP also stimulated IGFBP-1 synthesis, but PD98059 failed to block the cAMP effect. Conversely, a PKA inhibitor (H-89) inhibited the ability of cAMP, but not IL-1β to stimulate IGFBP-1 synthesis. The effect of IL-1β and cAMP on IGFBP-1 messenger RNA (mRNA) accumulation was additive. IL-1β, cAMP, PD98059, and H-89 had similar effects on the accumulation of IGFBP-1 protein and mRNA. IL-1β and cAMP did not change the half-life of IGFBP-1 mRNA, but PD98059 and SB202190, a p38 MAP kinase inhibitor, destabilized IGFBP-1 mRNA and blocked the phosphorylation of RSK-1 in response to IL-1β. Our data demonstrate that the MAP kinase signal transduction pathway plays an important role in the regulation of IGFBP-1 synthesis by IL-1β.",
author = "Frost, {Robert A.} and Nystrom, {Gerald J.} and Lang, {Charles H.}",
year = "2000",
month = "1",
day = "1",
doi = "10.1210/endo.141.9.7641",
language = "English (US)",
volume = "141",
pages = "3156--3164",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "9",

}

Stimulation of insulin-like growth factor binding protein-1 synthesis by interleukin-1β : Requirement of the mitogen-activated protein kinase pathway. / Frost, Robert A.; Nystrom, Gerald J.; Lang, Charles H.

In: Endocrinology, Vol. 141, No. 9, 01.01.2000, p. 3156-3164.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Stimulation of insulin-like growth factor binding protein-1 synthesis by interleukin-1β

T2 - Requirement of the mitogen-activated protein kinase pathway

AU - Frost, Robert A.

AU - Nystrom, Gerald J.

AU - Lang, Charles H.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Insulin-like growth factor (IGF) binding protein-1 (IGFBP-1) is a 28-kDa plasma protein that binds to IGF-I and IGF-II with high affinity. IGFBP-1 is elevated in the blood as a result of sepsis, AIDS, excessive alcohol consumption, and diabetes and may, in part, be responsible for the wasting observed during these pathophysiological conditions. The liver is the principal site of IGFBP-1 synthesis, and we have previously shown that proinflammatory cytokines can directly stimulate IGFBP-1 secretion in a human hepatoma cell line (HepG2). The purpose of the present study was to investigate the role of the MAP kinase pathway in regulating IGFBP-1 synthesis by IL-1β. We show that IL-1β stimulates the phosphorylation of ERK-1 and -2 in a time- and dose-dependent manner. In addition, the MAP kinase-kinase MEK-1 and the ribosomal S6-kinase RSK-1 are also phosphorylated in response to IL-1β. The transcription factor CREB, a potential substrate of both protein kinase A (PKA) and RSK-1, is phosphorylated in response to IL-1β and cAMP in HepG2 cells. The ability of IL-1β to stimulate the expression of IGFBP-1 and the phosphorylation of the above kinases was specifically inhibited by PD98059, a MEK-1 inhibitor, cAMP also stimulated IGFBP-1 synthesis, but PD98059 failed to block the cAMP effect. Conversely, a PKA inhibitor (H-89) inhibited the ability of cAMP, but not IL-1β to stimulate IGFBP-1 synthesis. The effect of IL-1β and cAMP on IGFBP-1 messenger RNA (mRNA) accumulation was additive. IL-1β, cAMP, PD98059, and H-89 had similar effects on the accumulation of IGFBP-1 protein and mRNA. IL-1β and cAMP did not change the half-life of IGFBP-1 mRNA, but PD98059 and SB202190, a p38 MAP kinase inhibitor, destabilized IGFBP-1 mRNA and blocked the phosphorylation of RSK-1 in response to IL-1β. Our data demonstrate that the MAP kinase signal transduction pathway plays an important role in the regulation of IGFBP-1 synthesis by IL-1β.

AB - Insulin-like growth factor (IGF) binding protein-1 (IGFBP-1) is a 28-kDa plasma protein that binds to IGF-I and IGF-II with high affinity. IGFBP-1 is elevated in the blood as a result of sepsis, AIDS, excessive alcohol consumption, and diabetes and may, in part, be responsible for the wasting observed during these pathophysiological conditions. The liver is the principal site of IGFBP-1 synthesis, and we have previously shown that proinflammatory cytokines can directly stimulate IGFBP-1 secretion in a human hepatoma cell line (HepG2). The purpose of the present study was to investigate the role of the MAP kinase pathway in regulating IGFBP-1 synthesis by IL-1β. We show that IL-1β stimulates the phosphorylation of ERK-1 and -2 in a time- and dose-dependent manner. In addition, the MAP kinase-kinase MEK-1 and the ribosomal S6-kinase RSK-1 are also phosphorylated in response to IL-1β. The transcription factor CREB, a potential substrate of both protein kinase A (PKA) and RSK-1, is phosphorylated in response to IL-1β and cAMP in HepG2 cells. The ability of IL-1β to stimulate the expression of IGFBP-1 and the phosphorylation of the above kinases was specifically inhibited by PD98059, a MEK-1 inhibitor, cAMP also stimulated IGFBP-1 synthesis, but PD98059 failed to block the cAMP effect. Conversely, a PKA inhibitor (H-89) inhibited the ability of cAMP, but not IL-1β to stimulate IGFBP-1 synthesis. The effect of IL-1β and cAMP on IGFBP-1 messenger RNA (mRNA) accumulation was additive. IL-1β, cAMP, PD98059, and H-89 had similar effects on the accumulation of IGFBP-1 protein and mRNA. IL-1β and cAMP did not change the half-life of IGFBP-1 mRNA, but PD98059 and SB202190, a p38 MAP kinase inhibitor, destabilized IGFBP-1 mRNA and blocked the phosphorylation of RSK-1 in response to IL-1β. Our data demonstrate that the MAP kinase signal transduction pathway plays an important role in the regulation of IGFBP-1 synthesis by IL-1β.

UR - http://www.scopus.com/inward/record.url?scp=0034455558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034455558&partnerID=8YFLogxK

U2 - 10.1210/endo.141.9.7641

DO - 10.1210/endo.141.9.7641

M3 - Article

C2 - 10965886

AN - SCOPUS:0034455558

VL - 141

SP - 3156

EP - 3164

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 9

ER -